B

Bergenbio ASA
OSE:BGBIO

Watchlist Manager
Bergenbio ASA
OSE:BGBIO
Watchlist
Price: 11.8 NOK -5.9% Market Closed
Market Cap: 479.2m NOK
Have any thoughts about
Bergenbio ASA?
Write Note

Bergenbio ASA
Total Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Bergenbio ASA
Total Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
B
Bergenbio ASA
OSE:BGBIO
Total Liabilities
kr41.4m
CAGR 3-Years
-14%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Hofseth Biocare ASA
OSE:HBC
Total Liabilities
kr261.6m
CAGR 3-Years
-1%
CAGR 5-Years
7%
CAGR 10-Years
7%
L
Lytix Biopharma AS
OSE:LYTIX
Total Liabilities
kr12.6m
CAGR 3-Years
0%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Arcticzymes Technologies ASA
OSE:AZT
Total Liabilities
kr22.9m
CAGR 3-Years
-14%
CAGR 5-Years
-6%
CAGR 10-Years
8%
N
Nykode Therapeutics ASA
OSE:NYKD
Total Liabilities
$27.8m
CAGR 3-Years
-14%
CAGR 5-Years
80%
CAGR 10-Years
N/A
T
Thor Medical ASA
OSE:TRMED
Total Liabilities
kr60.1m
CAGR 3-Years
-21%
CAGR 5-Years
-13%
CAGR 10-Years
24%
No Stocks Found

Bergenbio ASA
Glance View

Market Cap
461.2m NOK
Industry
Biotechnology

BerGenBio ASA engages in the development of biopharmaceutical product for cancer therapy. The company is headquartered in Bergen, Hordaland. The company went IPO on 2017-04-07. The firm's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) kinase inhibitors, small molecule AXL inhibitors, and antibody programs. Its flagship product is BGB324, an orally avaliable small molecule AXL kinase inhibitor. Inhibition of AXL kinase activity addresses an important mechanism in the evolution of cancer cell in terms of its aggressiveness, and focuses on creation of therapeutic options for cancer patients. The firm also performs a range of clinical trials for interested patients, primarily affected with acute myeloid leukemia and non-small cell lung cancer.

BGBIO Intrinsic Value
0.2 NOK
Overvaluation 98%
Intrinsic Value
Price
B

See Also

What is Bergenbio ASA's Total Liabilities?
Total Liabilities
41.4m NOK

Based on the financial report for Sep 30, 2024, Bergenbio ASA's Total Liabilities amounts to 41.4m NOK.

What is Bergenbio ASA's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
4%

Over the last year, the Total Liabilities growth was 54%. The average annual Total Liabilities growth rates for Bergenbio ASA have been -14% over the past three years , 4% over the past five years .

Back to Top